OSAKA and GENEVA, 4 October 2022 — Japanese pharmaceutical company Shionogi & Co., Ltd. and the Medicines Patent Pool (MPP), a United Nations-backed public health organisation, reflecting a shared commitment to increase access to life-saving medicines for low- and middle-income countries (LMICs), today announced that they have signed a voluntary licence agreement for Shionogi’s antiviral candidate ensitrelvir fumaric acid (S-217622). The agreement, signed yesterday at a ceremony held at Shionogi’s headquarters in Osaka, will enable MPP to facilitate additional production and distribution of the investigational antiviral, pending regulatory authorisation or approval, by granting sublicences to qualified generic manufacturers, with the goal of expanding access to people living in LMICs. Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
Read the full press release here.
SEE ALSO:
- Health Policy Watch: Shionogi and the Medicines Patent Pool reach agreement on COVID-19 antiviral pill
- Devex: MPP has a licensing deal for a new oral COVID-19 antiviral pill
Source : Medicines Patent Pool
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.